Searchable abstracts of presentations at key conferences in endocrinology

ea0022p631 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Correlation between GH and FSH in the cerebrospinal fluid and sleep respiratory events

Capatina Cristina , Niculescu Dan , Caragheorgheopol Andra , Coculescu Mihail

Introduction: There are high levels of anterior pituitary hormones in the cerebrospinal fluid (CSF), i.e. beyond the blood–brain barrier, in many patients with pituitary tumors.Aim: To assess the influence of CSF pituitary hormones on brain functions reflected by sleep architecture and sleep apnea.Method: Twenty-nine patients (17 women, 12 men) with pituitary adenomas (20 acromegaly, 5 nonfunctioning pituitary adenomas, 4 prol...

ea0021p296 | Pituitary | SFEBES2009

Cabergoline suppression test: assessment tool for management of hyperprolactinemia

Badiu Corin , Silvestro Luigi , Verzea Simona , Caragheorgheopol Andra

Cabergoline (CAB) is a selective dopamine D2-receptor agonist with long-lasting action, highly effective in treating micro- and macroprolactinoma. However, the clinical response to cabergoline can be seen only after several months of treatment, allowing the tumor shrinkage and decrease of prolactin. Despite most prolactinomas are responsive to CAB, there are up to 8% of cases in which tumor responsivity is limited. In order to asses the sensitivity to Cab, we aimed to develop ...

ea0014p166 | (1) | ECE2007

Cabergoline suppression test in distinguishing the variability of response to dopamine agonists in prolactinomas

BADIU Corin , VOICU Daniela , Caragheorgheopol Andra , Hortopan Dan , Silvestro Luigi

Primary therapy in prolactinomas, the most frequent pituitary adenomas, consists in ergot derivatives dopamine agonists (bromocriptine or cabergoline) which lowers prolactin levels and shrink the tumour. Bromocriptine was the first drug used, but the therapeutic levels are attained after several days/weeks, therefore an acute suppression test is not possible. However, the biological response is variable and 10% of prolactinomas are resistant to medical therapy. In order to eva...

ea0056p84 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2018

Metabolic and hormonal profile in primary aldosteronism as compared with essential hypertension

Trifanescu Raluca , Smarandoiu Alexandra , Caragheorgheopol Andra , Iordachescu Carmen , Poiana Catalina

Background: Primary aldosteronism is associated with increased vascular mortality and morbidity.Aims: We aimed to assess metabolic and hormonal profile differences in patients with primary aldosteronism (PA) compared with patients with essential hypertension (EH).Patients and methods: Thirty-one patients (11 M/20 F) with primary aldosteronism, aged 46.2±12.9 years and 64 patients (24 M/40 F) with essential hypertension, aged 4...

ea0073aep54 | Adrenal and Cardiovascular Endocrinology | ECE2021

Adrenal function recovery after successful surgery for Cushing

Marin Alexandra , Mihai Daniel , Caragheorgheopol Andra , Badiu Corin

BackgroundCushing syndrome (CS) is caused by prolonged exposure to elevated cortisol levels and it’s classified as either ACTH-dependent or ACTH independent CS. The most common form of endogenous ACTH CS is Cushing disease (CD); ACTH-independent CS is caused by various adrenal abnormalities. First-line therapy in CS is the resection of the underlying tumor in all cases. After surgical cure of CS, most patients develop transient secondary adrenal ins...

ea0081ep33 | Adrenal and Cardiovascular Endocrinology | ECE2022

Large adrenal tumor in paucisymptomatic ACTH – independent Cushing syndrome’s patient – a clinical case

Mohora Maria-Alexandra , Trifanescu Raluca , Andra Caragheorgheopol , Carmen Iordachescu , Dan Hortopan , Poiana Catalina

Background: Cushing’s syndrome is represented by the cummulation of signs and symptoms of excess glucocorticoids and has many potential causes. Approximately 20 percent of all cases are represented by ACTH-independent adrenal tumors – with a majority of these being represented by cortisol secreting adrenal adenomas. Generally, a large adrenal tumor has over 5 cm in diameter and the risk of it being malignant raises proportionately with the dimensions. Large adrenal t...

ea0081ep91 | Adrenal and Cardiovascular Endocrinology | ECE2022

Silent clinical presentation of a rare genetic disorder

Giuca Diandra Carmen , Hortopan Dan , Vladoiu Suzana , Padure Adriana , Caragheorgheopol Andra , Kremer Andreea , Gherlan Iuliana

Introduction: Carney complex is a rare autosomal dominant genetic disorder which develops secondary to mutation in the PRKAR1A gene located in the 17q22-24 region. It is commonly characterised by the association between spotty skin pigmentation, cardiac myxoma and secretory endocrine tumors.Case presentation: A 15.8-year-old boy known with PRKAR1A mutation diagnosed based on his personal history – cutaneous papiloma of the neck resected at the age o...

ea0050p297 | Neuroendocrinology and Pituitary | SFEBES2017

Recurrence rate of hyperprolactinemia after dopamine agonists withdrawal in macroprolactinoma patients

Trifanescu Raluca , Baranga Iuliana , Caragheorgheopol Andra , Dumitrascu Anda , Gheorghiu Monica , Poiana Catalina

Background: Dopamine agonists (DA) have excellent result in controlling both hyperprolactinemia and tumor volume in macroprolactinomas. However, even after long term DA treatment, withdrawal of dopamine agonists results in recurrence of hyperprolactinemia in a significant proportion of patients.Aim: To assess recurrence rate of hyperprolactinemia after DA withdrawal in a large series of patients treated in a tertiar...

ea0050p297 | Neuroendocrinology and Pituitary | SFEBES2017

Recurrence rate of hyperprolactinemia after dopamine agonists withdrawal in macroprolactinoma patients

Trifanescu Raluca , Baranga Iuliana , Caragheorgheopol Andra , Dumitrascu Anda , Gheorghiu Monica , Poiana Catalina

Background: Dopamine agonists (DA) have excellent result in controlling both hyperprolactinemia and tumor volume in macroprolactinomas. However, even after long term DA treatment, withdrawal of dopamine agonists results in recurrence of hyperprolactinemia in a significant proportion of patients.Aim: To assess recurrence rate of hyperprolactinemia after DA withdrawal in a large series of patients treated in a tertiar...

ea0090p37 | Calcium and Bone | ECE2023

Vertebral fractures in acromegaly

Sorohan Madalina , Baciu Ionela , Galoiu Simona , Caragheorgheopol Andra , Iordachescu Carmen , Poiana Catalina

Introduction: Acromegalic bone disease is characterized by an increased prevalence of fragility vertebral fractures (VFs). However, an effective, non-invasive and cost-efficient imaging technique that can diagnose early bone alterations in this category of patients is yet to found. The use of bone mineral density (BMD) is not as useful as in other causes of osteoporosis as excess GH leads to specific microarchitectural alteration of trabecular bone, which don’t translate ...